替雷利珠单抗辅助仑伐替尼治疗原发性肝癌的临床疗效研究

Clinical efficacy of tirelizumab combined with lenvatinib in the treatment of primary liver cancer

目的:探究替雷利珠单抗辅助仑伐替尼治疗原发性肝癌(Primary liver cancer,PLC)的临床疗效。方法:于2020年1月至2023年5月赣州市南康区第一人民医院收治的PLC患者中选取60例作为研究对象,并按随机数字表法分成对照组(30例)和实验组(30例)。对照组给予仑伐替尼治疗,实验组给予替雷利珠单抗辅助仑伐替尼治疗,时长为12 w。于治疗结束后参考实体瘤疗效评估标准比较两组的疗效,于治疗前和治疗结束后检测两组的免疫功能(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))水平和肝功能(总胆红素(Total bilirubin,TBIL)、谷丙转氨酶(Alanine transaminase,ALT)、谷草转氨酶(Aspertate aminotransferase,AST))并比较两组间的差异,同时参考常见不良反应事件评价标准比较两组治疗期间药物毒性反应发生率。结果:实验组治疗后的客观缓解率66.67%,高于对照组40.00%(P<0.05);与治疗前相比,两组的CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)均增加(P<0.05),其中实验组更为显著,差异有统计学意义(P<0.05);两组的TBIL、ALP、ALT、AST水平均降低(P<0.05),其中实验组更为显著,差异有统计学意义(P<0.05);两组药物毒性反应发生率差异无统计意义(P>0.05)。结论:替雷利珠单抗辅助仑伐替尼治疗PLC的临床疗效显著,能有效提高免疫功能,改善肝功能,且应用较安全。

Objective:To investigate the clinical efficacy of tirelizumab combined with lenvatinib in the treatment of primary liver cancer(PLC).Methods:Sixty PLC patients admitted to our hospital from January 2020 to May 2023 were selected as research subjects and randomly divided into a control group(30 cases)and an experimental group(30 cases)using a random number table method.The control group was treated with lenvatinib,while the experimental group was treated with tirelizumab combined with Lenvatinib,all for 12 weeks.Compare the differences in efficacy,immune function(CD4+,CD8+,CD4+/CD8+)levels,liver function(total bilirubin(TBIL),alanine aminotransferase(ALT),aspartate aminotransferase(AST)),and incidence of drug toxicity between the two groups.Results:The objective remission rate of the experimental group after treatment was 66.67%,which was higher than the control group of 40.00%(P<0.05);Compared with before treatment,the CD4+,CD8+,CD4+/CD8+levels in both groups increased(P<0.05),with the experimental group being more significant(P<0.05);The levels of TBIL,ALP,ALT,and AST in both groups decreased(P<0.05),with the experimental group being more significant(P<0.05);There was no statistically significant difference in the incidence of toxic reactions between the two groups of drugs(P>0.05).Conclusion:The clinical efficacy of tirelizumab combined with lenvatinib in the treatment of PLC is significant,which can effectively improve immune function and liver function,and its application is relatively safe.